All News
🧫 JAKi and NK
cells activation:
JAKi and particularly TOFA impacts NK cells:
*phenotype
*function
*impairs the control of proliferation of lung cancer and lymphoma cell lines
An explanation for the increase of cancer events in ORAL surveillance?
@RheumNow #EULAR2022 OP0265 https://t.co/LzMLdzcsDU
Aurelie Najm AurelieRheumo ( View Tweet)
MACE events no diff in German RA Rabbit registry of only humans shows #baricitinib and #tofacitinib vs #TNFis @RheumNow @eular_org #EULAR2022 OP0135 https://t.co/O8iOA7jpal
Janet Pope Janetbirdope ( View Tweet)
#EULAR2022 OP0274
Hospitalization for TB and other opportunistic infxn (OI) w inflamm joint disease:
⭐️9% with RA, 6% with PsA and AS in Western Australia
⭐️Decrease overall since 1985, but recent increase
⭐️Sharp rise of mycotic infections
⭐️No PJP, likely due to ppx
@Rheumnow
Eric Dein ericdeinmd ( View Tweet)
Low socioeconomic status should on the list as a high risk factor (#notJUSTrace) https://t.co/zikGGLISSN
TheDaoIndex KDAO2011 ( View Tweet)
Yoshimura et al. 10 year findings of TOMORROW study. Glucocorticoid use of even 2mg/day is fracture risk in RA! @RheumNow #EULAR2022 POS0631 https://t.co/c8uCdPzUiE
Richard Conway RichardPAConway ( View Tweet)
Visual symptoms in GCA: should we take it on face value?
@cmukhtyar group tertiary rheum/ophthal
n=350 consecutive GCA pts diagnosed (bx/PET)
visual symptoms 29%
ocular signs 13%
Not all symptoms = signs
No doubt not all symptoms of same concern
POS0810 #EULAR2022 @RheumNow https://t.co/TYHylpBhkN
David Liew drdavidliew ( View Tweet)
@Yuz6Yusof on breakthrough infections & severe #COVID in RTX treatment #EULAR2022
🦠Rate of mod/severe COVID infection comparable to pre-pandemic severe infection rate
💉High vaccination rate prevented severe disease
📊Consider #comorbidities & low IgG in risk-benefit assessment https://t.co/PGUVbHD7i2
Mrinalini Dey DrMiniDey ( View Tweet)
BE COMPLETE RCT
Bimekizumab vs. PBO in TNFiIR PsA pts
meets its primary criteria at 16wks w/
-ACR50 43%
-PASI 90 69%
and MDA achieved in 40+% pts
No new safety signal.
@RheumNow #EULAR2022 OP0255 https://t.co/QazYlzDqIc
Aurelie Najm AurelieRheumo ( View Tweet)
Study of 184 #SLE pts shows that major infections in SLE results in a 7 fold increased risk of a major lupus flare. Abst# OP0143 #EULAR2022 https://t.co/yMJcMAFSh6
Dr. John Cush RheumNow ( View Tweet)
RA & dementia - it's getting more damning
RA dementia risk: HR 1.25
from Korean nationwide data: RA n=138,592
this follows @MyasoedovaElena's data
RA systemic inflamm leading to dementia (AD, vascular)?
Need to understand if any DMARD protective
OP0271 #EULAR2022 @RheumNow https://t.co/4V7fOtVlnj
David Liew drdavidliew ( View Tweet)
Merola et al. IL23i Risankizumab in PsA. Proportion achieving ACR20 week24 by subgroup. Effective across all groups. Similar irrespective of demographics, disease characteristics, concomittent meds, prior bDMARD use. @RheumNow #EULAR2022 POS1032 https://t.co/GAVKFpwCst
Richard Conway RichardPAConway ( View Tweet)
#EULAR2022 OP0275: RA-ILD after transplant by @AARazmjou
⭐️UIP #1 cause RA-ILD, worst prognosis - 68% of transplanted pts
⭐️UIP seen in 88% of deceased patients, 56% of living
⭐️Median survival 5.3 years
@RheumNow https://t.co/tGBQ5GBlVg
Eric Dein ericdeinmd ( View Tweet)
Promising! Prof Schett presents the 1st 5 #SLE pts who received CAR T cell therapy - all went into sustained remission off of meds: new B cells reconstituted at 100 days but SLE did not. OP0279 #EULAR2022 @rheumnow https://t.co/o3Ehp55C4Q
TheDaoIndex KDAO2011 ( View Tweet)
Mestre-Torres et al. Features at GCA diagnosis that predict permanent vision loss. Age>75, jaw claudication, amaurosis fugax increase risk. Systemic symptoms decrease risk @RheumNow #EULAR2022 POS0271 https://t.co/FPC9R1v8S3
Richard Conway RichardPAConway ( View Tweet)
FAP tracer-based PET-CT ☄️ (68Ga-FAPI-04)
⚡️Detects metabolic activity and tissular inflammation
⚡️Correlates with MRI changes in PsA
⚡️Is associated
w/ progression of joint damage
⚡️Is sensitive to change
An exciting new imaging modality!
@RheumNow OP0256 #EULAR2022 https://t.co/16Z1R71YjC
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2022 OP0273
Difficult to treat RA (D2TRA):
⭐️Lower socioeconomic treatment
⭐️RF positivity
⭐️Higher inflammatory markers
⭐️ILD
⭐️Lower proportion on MTX, better response to JAKi and RTX
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
Was ORAL Surveillance really a surprise?
Let's look post-hoc at all the other tofacitinib RCTs (ph 1-3b/4 +LTE)
Cardiovascular risk-enriched pts were always in the same MACE ballpark with tofa
ORAL Surveillance was worse, but clues were always there
OP0264 #EULAR2022 @RheumNow https://t.co/rB5SwVX2oc
David Liew drdavidliew ( View Tweet)
GLORIA trial presented by Martin Boxers. 2 yr RCT, 5mg Pred vs. PBO shows DAS28 benefit (-0.37 to -0.62) & -1.7 better X-ray (vs PBO) at 2yrs. BUT signif more harm (AE) RR 1.24; mostly infx. Is this a good trade off? Abst# OP0263 #EULAR2022 https://t.co/kBiRYxXXZe
Dr. John Cush RheumNow ( View Tweet)
#OP0247 #EULAR2022 Prof Mease analysed US Database (>1 million) pre- & post-Omicron using machine learning.Factors assoc with poor #COVID outcomes in IMID:age & comorbidities. Vaccination was protective. JAK-I and RTX increased risk weakly initially but not post-Omicron @RheumNow https://t.co/JCqTZvPgll
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Risk of haematological malignancy in PsA
Nordic cohorts
*40 events, IR 67/100 000 person-years
*NO difference between PsA bionaive and TNFi treated
BUT *⬆️ in PsA vs. matched controls
*no difference between myeloid and lymphoid malignancies.
OP0257 #EULAR2022 @RheumNow https://t.co/oIojobgDP3
Aurelie Najm AurelieRheumo ( View Tweet)